Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carfilzomib.

Monika Engelhardt1,2, Magdalena Szymaniak-Vits3, Stefanie Ajayi3,4

  • 1Hematology and Oncology, Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. monika.engelhardt@uniklinik-freiburg.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Nature medicine·2026
Same author

Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.

HemaSphere·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Transfusion·2026
Same author

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2026
Same author

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Annals of hematology·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles
This summary is machine-generated.

Carfilzomib (CFZ) is a proteasome inhibitor showing significant efficacy in relapsed or refractory multiple myeloma (RRMM). It offers good responses and survival benefits, with a manageable safety profile compared to other treatments.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Carfilzomib (CFZ) is a second-generation proteasome inhibitor (PI) with demonstrated activity in relapsed or refractory multiple myeloma (RRMM).
  • CFZ exhibits selective, irreversible binding to its target, inducing antiproliferative and proapoptotic effects in cancer cells.

Purpose of the Study:

  • To review the efficacy and safety of carfilzomib in RRMM.
  • To highlight its use in various combination regimens and ongoing investigations.

Main Methods:

  • Review of completed and ongoing clinical studies involving carfilzomib.
  • Analysis of efficacy data (response rates, PFS, OS) and safety profiles.

Main Results:

  • CFZ monotherapy and combinations (e.g., Kd, KRd) show significant responses, PFS, and OS in RRMM.
Keywords:
CarfilzomibIrreversibleMultiple myelomaNovel proteasome inhibitorRelapsed/refractory disease

Related Experiment Videos

  • CFZ has a tolerable safety profile with lower neuropathy incidence than bortezomib (BTZ), though cardiotoxicity requires monitoring.
  • FDA and EMA approvals support CFZ use in RRMM and its evaluation in newly diagnosed MM (NDMM) and smoldering MM.

    • Conclusions:

    • Carfilzomib is an effective treatment option for RRMM, offering survival benefits.
    • Ongoing research explores its role in various combinations and earlier lines of therapy, including NDMM.